Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as a significant stock within the Renaissance Technologies Portfolio [1] - JPMorgan analyst Chris Schott raised the price target for Gilead from $135 to $145, maintaining an Overweight rating [2] - The adjustment indicates a 29% upside potential for Gilead from its closing share price on September 22 [2] - Wall Street analysts generally hold a positive outlook on Gilead, with a consensus Buy rating [2] Company Overview - Gilead Sciences, Inc. is a biopharmaceutical company focused on developing medicines for life-threatening diseases such as HIV, viral hepatitis, and cancer [3]